Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CHF 13.34
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline...
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers. In particular, the stock is undervalued on P/FCF.
Data is available to registered users only
Buy
Sell